BioXcel Therapeutics (BTAI) Accumulated Depreciation (2017 - 2026)

BioXcel Therapeutics' Accumulated Depreciation history runs 10 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 17.87% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (up 17.87% YoY), while the FY2025 annual figure was $1.8 million, up 19.97% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $1.9 million, up from $1.8 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $1.9 million in Q1 2026, with the low at $679000.0 in Q1 2022.
• The 5-year median for Accumulated Depreciation is $1.3 million (2024), against an average of $1.3 million.
• The sharpest annual moves came in 2022 and 2026: Accumulated Depreciation soared 61.22% in 2022, then gained 17.87% in 2026.
• BioXcel Therapeutics' Accumulated Depreciation stood at $885000.0 in 2022, then surged by 34.8% to $1.2 million in 2023, then gained by 25.9% to $1.5 million in 2024, then grew by 19.97% to $1.8 million in 2025, then advanced by 3.22% to $1.9 million in 2026.
• Business Quant data shows BTAI's Accumulated Depreciation at $1.9 million in Q1 2026, $1.8 million in Q4 2025, and $1.7 million in Q3 2025.